Additional file 3 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 3: Supplementary table 2. Univariate and Multivariate analysis of prognostic factors affecting CS

Additional file 1 of Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease

Additional file 1: Table S1. Statins used in study subjects. Table S2. Endpoint events for study subjects. Table S3. Univariate COX analysis of risk factors for MACE

Additional file 5 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 5: Supplementary table 3. Discriminatory ability of clinicopathological factors in predicting OS in gastric cancer

Additional file 2 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 2: Supplementary table 1. Univariate and Multivariate analysis of prognostic factors affecting OS

Additional file 8 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 8

Additional file 4 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 4: Supplementary figure 2. Heatmap of C-index of clinicopathological factors in predicting CSS and OS in gastric cancer

Additional file 6 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 6: Supplementary table 4. C-index of clinicopathological factors in subgroup

Additional file 1 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 1. Material and Methods

Additional file 7 of Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Additional file 7: Supplementary figure 3. Survival analysis of CSS and OS stratified by tumor size

Simultaneous Enantioselective Determination of the Chiral Fungicide Prothioconazole and Its Major Chiral Metabolite Prothioconazole-Desthio in Food and Environmental Samples by Ultraperformance Liquid Chromatography–Tandem Mass Spectrometry

An efficient and sensitive chiral analytical method was established for the determination of the chiral fungicide prothioconazole and its major chiral metabolite prothioconazole-desthio in agricultural and environmental samples using ultraperformance liquid chromatography–tandem mass spectrometry. The optical rotation and absolute configuration of enantiomers were identified by optical rotation detector and electronic circular dichroism spectra. The elution order of prothioconazole and its chiral metabolite enantiomers was <i>R</i>-(+)-prothioconazole-desthio, <i>S</i>-(−)-prothioconazole-desthio, <i>R</i>-(−)-prothioconazole, and <i>S</i>-(+)-prothioconazole. The mean recoveries from the samples was 71.8–102.0% with intraday relative standard deviations (RSDs) of 0.3–11.9% and interday RSDs of 0.9–10.6%. The formation of prothioconazole-desthio was studied in soil under field conditions and enantioselective degradation was observed for chiral prothioconazole. Remarkable enantioselective degradation was observed: <i>R</i>-prothioconazole degraded preferentially with EF values from 0.48 to 0.37. Although prothioconazole-desthio is the most remarkably bioactive metabolite, no obvious enantioselective behavior was observed in soil. These results may help to systematically evaluate prothioconazole and its metabolites in food and environmental safety